摘要
目的:评价钠葡萄糖共转运蛋白2抑制剂致急性胰腺炎的风险。方法:检索美国FDA不良事件报告系统中2013年1月1日至2020年10月31日的数据,采用报告比值比法(ROR)分析钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂与急性胰腺炎的相关性。结果:共检索到SGLT-2抑制剂致急性胰腺炎报告264份,整体SGLT-2抑制剂、卡格列净、恩格列净和达格列净致急性胰腺炎事件的ROR分别为4.95(95%CI:4.37~5.59),4.34(95%CI:3.59~5.24),4.27(95%CI:3.42~5.32)和8.06(95%CI:6.44~10.09)。联合用药分析显示,SGLT-2抑制剂与胰高血糖素样肽1(GLP-1)类似物联合用药致急性胰腺炎的ROR为8.81(95%CI:6.72~11.56),与不联用GLP-1类似物相比ROR增加了99.32%。SGLT-2抑制剂与二肽基肽酶4(DPP-4)抑制剂联合用药致急性胰腺炎的ROR为8.40(95%CI:6.35~11.1),与不联用DPP-4抑制剂相比ROR增加了87.92%。结论:SGLT-2抑制剂可能增加急性胰腺炎风险,联合应用DPP-4抑制剂或GLP-1类似物时,急性胰腺炎的发生风险明显增加。
OBJECTIVE To evaluate the risk of acute pancreatitis caused by sodium-glucose cotransporter 2(SGLT-2)inhibitors.METHODS Reports of acute pancreatitis induced by SGLT-2 inhibitors from January 2013 to October 2020 were retrieved from the US FDA Adverse Event Reporting System.Report odds ratio was utilized for analyzing the correlation between SGLT-2 inhibitors and acute pancreatitis. RESULTS A total of 264 cases of acute pancreatitis caused by SGLT-2 inhibitors were retrieved.The report odds ratio(ROR)of acute pancreatitis caused by overall SGLT-2 inhibitors of canagliflozin, dapagliflozin and empagliflozin were 4.95(95%CI:4.37-5.59),4.34(95%CI:3.59-5.24),4.27(95%CI:3.42-5.32)and 8.06(95%CI:6.44-10.09)respectively.The analysis of combined medication showed that the ROR of acute pancreatitis caused by the combination of SGLT-2 inhibitor and glucagon-like peptide-1(GLP-1)analogue was 8.81(95%CI:6.72-11.56)with an increment of 99.32% as compared with that not co-using GLP-1 analogue.The ROR of acute pancreatitis caused by the combination of SGLT-2 inhibitors and dipeptidyl peptidase-4(DPP-4)inhibitors was 8.40(95%CI:6.35-11.1)with an increment of 87.92% as compared with that not co-using DPP-4 inhibitors. CONCLUSION GLT-2 inhibitors may increase the risk of acute pancreatitis.When co-using with DPP-4 inhibitors or GLP-1 analogue, the risk is markedly elevated.
作者
赵敏
黄承龙
黄振光
钟秋安
ZHAO Min;HUANG Cheng-long;HUANG Zhen-guang;ZHONG Qiu-an(School of Public Health,Guangxi Medical University,Guangxi Nanning 530021,China;Department of Pharmacy,First Affiliated Hospital,Guangxi Medical University,Guangxi Nanning 530021,China)
出处
《中国医院药学杂志》
CAS
北大核心
2021年第8期816-819,共4页
Chinese Journal of Hospital Pharmacy
基金
广西高校中青年教师科研基础能力提升项目(编号:2020KY03047)。
